Threshold Pharmaceuticals, Inc.  

(Public, NASDAQ:THLD)   Watch this stock  
Find more results for Robert L. Tillman
-0.17 (-4.19%)
After Hours: 3.89 0.00 (0.00%)
Oct 12, 4:28PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.86 - 4.08
52 week 2.58 - 5.28
Open 4.08
Vol / Avg. 0.00/807,631.00
Mkt cap 289.62M
P/E     -
Div/yield     -
EPS -0.51
Shares 71.33M
Beta 3.26
Inst. own 61%
Sep 10, 2015
Threshold Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference
Jul 30, 2015
Q2 2015 Threshold Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -225.71% -146.61%
Operating margin -242.96% -212.27%
EBITD margin - -203.38%
Return on average assets -41.16% -25.02%
Return on average equity - -
Employees 63 -
CDP Score - -


Suite 300, 170 Harbor Way
United States - Map
+1-650-4748200 (Phone)
+1-650-4742529 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Threshold Pharmaceuticals, Inc. (Threshold) is a biotechnology company engaged in the discovery and development of therapeutic agents that selectively target tumor cells for the treatment of patients living with cancer. Threshold's investigational small molecule, evofosfamide, is being evaluated in two Phase III clinical trials, one registrational Phase II clinical trial and various earlier-stage clinical trials for the treatment of various diseases, such as soft tissue sarcoma, pancreatic cancer, non-squamous non-small cell lung cancer (n-s NSCLC), advanced melanoma, multiple myeloma and advanced solid tumors. Threshold has also licensed rights to a development program based on the clinical-stage oncology compound TH-4000, a hypoxia-targeted epidermal growth factor receptor (EGFR), tyrosine kinase inhibitor. Threshold's [18F]-HX4 is an investigational Positron Emission Tomography (PET) imaging agent for hypoxia to identify and quantify the degree of hypoxia in tumors in vivo.

Officers and directors

Harold E. Selick Ph.D. Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Stewart M. Kroll Senior Vice President, Clinical Development
Age: 56
Bio & Compensation  - Reuters
Robert L. Simon Senior Vice President - Regulatory Affairs and Quality Assurance
Age: 70
Bio & Compensation  - Reuters
Joel A. Fernandes Vice President - Finance, Controller
Age: 45
Bio & Compensation  - Reuters
Nipun Davar Ph.D. Vice President - Pharmaceutical Development and Manufacturing
Age: 47
Bio & Compensation  - Reuters
Tillman Pearce M.D. Chief Medical Officer
Age: 58
Bio & Compensation  - Reuters
Jeffrey W. Bird Independent Director
Age: 54
Bio & Compensation  - Reuters
Bruce C. Cozadd Independent Director
Age: 51
Bio & Compensation  - Reuters
David R. Hoffmann Independent Director
Age: 70
Bio & Compensation  - Reuters
Wilfred E. Jaeger M.D. Independent Director
Age: 50
Bio & Compensation  - Reuters